Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020 caused about 400,000 deaths. Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leuk...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sara Galimberti, Mario Petrini, Claudia Baratè, Federica Ricci, Serena Balducci, Susanna Grassi, Francesca Guerrini, Elena Ciabatti, Sandra Mechelli, Antonello Di Paolo, Chiara Baldini, Laura Baglietto, Lisa Macera, Pietro Giorgio Spezia, Fabrizio Maggi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2020-09-01
Serie:	Frontiers in Oncology
Soggetti:	CML TKIs imatinib nilotinib TTV immunity
Accesso online:	https://www.frontiersin.org/article/10.3389/fonc.2020.01428/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!